Morbi pretium leo et nisl aliquam mollis. Quisque arcu lorem, ultricies quis pellentesque nec, ullamcorper eu odio.
Rollman Management, a globally recognized investor in innovative technologies, confirms a $5 million investment in Pharmatech AI, a German company leveraging artificial intelligence (AI) to transform pharmaceutical research. The funding will support the expansion of a state-of-the-art research center in Germany and the rollout of the PCH Token, which bridges the pharmaceutical industry with the crypto ecosystem. Pharmatech AI had recently drawn significant attention with its massive 620,000 m² research facility, positioning itself as a pioneer in AI-driven drug research and sustainable pharmaceutical innovation.
Germany leads in medical research with top-tier infrastructure, skilled experts, and a strong regulatory framework. Collaboration with the Federal Institute for Drugs and Medical Devices (BfArM) and EU programs, alongside ICH M7 guidelines for AI-driven models like predictive toxicology, drives innovation. GDPR compliance ensures trust, while the pharmaceutical industry invests over €8 billion annually, gaining global acclaim. The global drug research market is set to reach $137.72 billion by 2029, with AI in drug research projected at $7.1 billion and medical cannabis at $41.4 billion by 2030. McKinsey predicts AI could save $60-110 billion yearly by cutting development times by up to 40%. Pharmatech AI’s focus on AI-driven cannabinoid research fills a critical gap, drawing interest from major pharmaceutical players and positioning it as a leader in a rapidly expanding market.
The integration of AI into drug research is subject to stringent regulatory requirements. The EU’s MiCA regulation provides clarity for digital assets, enabling investors to directly fund research projects with confidence. Good Manufacturing Practices (GMP) ensure the quality and safety of production processes. Pharmatech AI addresses these demands through transparent algorithms and protocols that comply with GDPR and GMP standards, ensuring data security and regulatory adherence. The company’s AI Multi-Drug Interaction Predictor (AI-MDIP), which uses Graph Neural Networks to analyze molecular interactions, demands high-performance computing resources. Pharmatech AI’s 620,000 m² research center in Germany, including 120,000 m² of indoor facilities for sustainable cannabis production for research purposes, which has been greatly facilitated by legalization. This requires significant resources for maintenance and expansion. Rollman Management’s $5 million investment will allow Pharmatech AI to significantly upgrade its computing infrastructure, hire more AI experts, and further expand its research center.
Pharmatech AI’s research center, powered by 55 MWp solar energy and designed to be CO2-neutral, supports sustainable production. Its AI-MDIP model predicts interactions, including cannabis-specific compounds, while the AI-powered cannabis lab generates thousands of data points per cycle for precise analytics. The funding will support AI-MDIP development, global pharmaceutical partnerships, and PCH Token expansion.
Rollman Management is a global business consulting and services firm specialised in emerging technologies for both traditional and transformative industries, driven by the firm belief that optimisation is not an end in itself but an opportunity to better the world of tomorrow.
The firm seeks to invest in talented teams and their blockchain protocols to further develop their technology and business while adding significant value to the future of the modern economy.
More details are available at rollmanmanagement.com.
